CATALYST PHARMACEUTICALS INC (CPRX) Stock Fundamental Analysis

NASDAQ:CPRX • US14888U1016

23.99 USD
+0.11 (+0.46%)
Last: Mar 3, 2026, 11:22 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

We assign a fundamental rating of 7 out of 10 to CPRX. CPRX was compared to 520 industry peers in the Biotechnology industry. CPRX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CPRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes CPRX very considerable for value and quality investing!


Dividend Valuation Growth Profitability Health

8

1. Profitability

1.1 Basic Checks

  • In the past year CPRX was profitable.
  • CPRX had a positive operating cash flow in the past year.
  • CPRX had positive earnings in 4 of the past 5 years.
  • CPRX had a positive operating cash flow in 4 of the past 5 years.
CPRX Yearly Net Income VS EBIT VS OCF VS FCFCPRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • CPRX has a Return On Assets of 20.69%. This is amongst the best in the industry. CPRX outperforms 96.73% of its industry peers.
  • CPRX has a Return On Equity of 23.65%. This is amongst the best in the industry. CPRX outperforms 96.15% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 21.23%, CPRX belongs to the top of the industry, outperforming 97.88% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for CPRX is in line with the industry average of 18.99%.
  • The last Return On Invested Capital (21.23%) for CPRX is above the 3 year average (20.37%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROIC 21.23%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
CPRX Yearly ROA, ROE, ROICCPRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

1.3 Margins

  • The Profit Margin of CPRX (37.64%) is better than 97.12% of its industry peers.
  • CPRX's Profit Margin has been stable in the last couple of years.
  • CPRX has a better Operating Margin (44.78%) than 99.23% of its industry peers.
  • CPRX's Operating Margin has improved in the last couple of years.
  • CPRX has a better Gross Margin (85.68%) than 88.08% of its industry peers.
  • CPRX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
CPRX Yearly Profit, Operating, Gross MarginsCPRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • CPRX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CPRX Yearly Shares OutstandingCPRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
CPRX Yearly Total Debt VS Total AssetsCPRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

  • CPRX has an Altman-Z score of 16.10. This indicates that CPRX is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 16.10, CPRX belongs to the best of the industry, outperforming 87.31% of the companies in the same industry.
  • CPRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.1
ROIC/WACC2.47
WACC8.61%
CPRX Yearly LT Debt VS Equity VS FCFCPRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 6.62 indicates that CPRX has no problem at all paying its short term obligations.
  • CPRX has a Current ratio of 6.62. This is in the better half of the industry: CPRX outperforms 66.92% of its industry peers.
  • CPRX has a Quick Ratio of 6.40. This indicates that CPRX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CPRX (6.40) is better than 65.38% of its industry peers.
Industry RankSector Rank
Current Ratio 6.62
Quick Ratio 6.4
CPRX Yearly Current Assets VS Current LiabilitesCPRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 29.01% over the past year.
  • CPRX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 32.75% yearly.
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%

3.2 Future

  • CPRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.46% yearly.
  • The Revenue is expected to grow by 9.11% on average over the next years. This is quite good.
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CPRX Yearly Revenue VS EstimatesCPRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
CPRX Yearly EPS VS EstimatesCPRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 14.20, the valuation of CPRX can be described as correct.
  • CPRX's Price/Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 95.96% of the companies in the same industry.
  • When comparing the Price/Earnings ratio of CPRX to the average of the S&P500 Index (27.13), we can say CPRX is valued slightly cheaper.
  • A Price/Forward Earnings ratio of 12.42 indicates a correct valuation of CPRX.
  • CPRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. CPRX is cheaper than 97.12% of the companies in the same industry.
  • CPRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.11, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.2
Fwd PE 12.42
CPRX Price Earnings VS Forward Price EarningsCPRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CPRX is valued cheaper than 98.08% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CPRX indicates a rather cheap valuation: CPRX is cheaper than 97.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 12.48
EV/EBITDA 7.5
CPRX Per share dataCPRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CPRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of CPRX may justify a higher PE ratio.
PEG (NY)0.99
PEG (5Y)0.43
EPS Next 2Y13.06%
EPS Next 3Y6.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CPRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CATALYST PHARMACEUTICALS INC

NASDAQ:CPRX (3/3/2026, 11:22:50 AM)

23.99

+0.11 (+0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-05
Inst Owners86.97%
Inst Owner Change-0.4%
Ins Owners5.48%
Ins Owner Change1.13%
Market Cap2.93B
Revenue(TTM)N/A
Net Income(TTM)217.63M
Analysts88.57
Price Target35.19 (46.69%)
Short Float %8.4%
Short Ratio7.66
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.08%
Min EPS beat(2)4.13%
Max EPS beat(2)24.03%
EPS beat(4)4
Avg EPS beat(4)21.33%
Min EPS beat(4)4.13%
Max EPS beat(4)29.76%
EPS beat(8)7
Avg EPS beat(8)16.56%
EPS beat(12)10
Avg EPS beat(12)13.3%
EPS beat(16)12
Avg EPS beat(16)8.79%
Revenue beat(2)2
Avg Revenue beat(2)4.27%
Min Revenue beat(2)2.19%
Max Revenue beat(2)6.34%
Revenue beat(4)4
Avg Revenue beat(4)4.39%
Min Revenue beat(4)2.19%
Max Revenue beat(4)6.34%
Revenue beat(8)7
Avg Revenue beat(8)3.51%
Revenue beat(12)11
Avg Revenue beat(12)3.34%
Revenue beat(16)13
Avg Revenue beat(16)2.97%
PT rev (1m)0.21%
PT rev (3m)0%
EPS NQ rev (1m)-0.44%
EPS NQ rev (3m)15.86%
EPS NY rev (1m)0.19%
EPS NY rev (3m)10.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.91%
Valuation
Industry RankSector Rank
PE 14.2
Fwd PE 12.42
P/S 5.07
P/FCF 12.48
P/OCF 12.48
P/B 3.18
P/tB 3.7
EV/EBITDA 7.5
EPS(TTM)1.69
EY7.04%
EPS(NY)1.93
Fwd EY8.05%
FCF(TTM)1.92
FCFY8.01%
OCF(TTM)1.92
OCFY8.01%
SpS4.73
BVpS7.54
TBVpS6.48
PEG (NY)0.99
PEG (5Y)0.43
Graham Number16.93
Profitability
Industry RankSector Rank
ROA 20.69%
ROE 23.65%
ROCE 28.06%
ROIC 21.23%
ROICexc 84.1%
ROICexgc 187.79%
OM 44.78%
PM (TTM) 37.64%
GM 85.68%
FCFM 40.59%
ROA(3y)18.85%
ROA(5y)22.43%
ROE(3y)22.87%
ROE(5y)26.38%
ROIC(3y)20.37%
ROIC(5y)19.67%
ROICexc(3y)162.63%
ROICexc(5y)159.51%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)26.92%
ROCE(5y)25.99%
ROICexgc growth 3Y8.72%
ROICexgc growth 5YN/A
ROICexc growth 3Y-30.16%
ROICexc growth 5YN/A
OM growth 3Y2.16%
OM growth 5Y5%
PM growth 3Y5.91%
PM growth 5Y1.34%
GM growth 3Y0.61%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.55
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.31%
Cap/Sales 0.02%
Interest Coverage 593.88
Cash Conversion 79.12%
Profit Quality 107.83%
Current Ratio 6.62
Quick Ratio 6.4
Altman-Z 16.1
F-Score6
WACC8.61%
ROIC/WACC2.47
Cap/Depr(3y)0.72%
Cap/Depr(5y)100.44%
Cap/Sales(3y)0.06%
Cap/Sales(5y)0.18%
Profit Quality(3y)162.12%
Profit Quality(5y)139.35%
High Growth Momentum
Growth
EPS 1Y (TTM)29.01%
EPS 3Y31.69%
EPS 5Y32.75%
EPS Q2Q%-6.82%
EPS Next Y14.31%
EPS Next 2Y13.06%
EPS Next 3Y6.95%
EPS Next 5Y25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%7.61%
Revenue Next Year7.82%
Revenue Next 2Y8.79%
Revenue Next 3Y8.45%
Revenue Next 5Y9.11%
EBIT growth 1Y48.97%
EBIT growth 3Y55%
EBIT growth 5Y43.74%
EBIT Next Year76.08%
EBIT Next 3Y25.59%
EBIT Next 5YN/A
FCF growth 1Y83.47%
FCF growth 3Y59.11%
FCF growth 5Y47.22%
OCF growth 1Y83.42%
OCF growth 3Y58.35%
OCF growth 5Y47.28%

CATALYST PHARMACEUTICALS INC / CPRX FAQ

What is the ChartMill fundamental rating of CATALYST PHARMACEUTICALS INC (CPRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to CPRX.


What is the valuation status for CPRX stock?

ChartMill assigns a valuation rating of 7 / 10 to CATALYST PHARMACEUTICALS INC (CPRX). This can be considered as Undervalued.


Can you provide the profitability details for CATALYST PHARMACEUTICALS INC?

CATALYST PHARMACEUTICALS INC (CPRX) has a profitability rating of 8 / 10.


What is the expected EPS growth for CATALYST PHARMACEUTICALS INC (CPRX) stock?

The Earnings per Share (EPS) of CATALYST PHARMACEUTICALS INC (CPRX) is expected to grow by 14.31% in the next year.